News

New iPSC-derived opti-ox™ powered disease model cells with the potential to advance frontotemporal dementia research and drug disc...

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

In this episode of the SynBioBeta podcast, bit.bio CEO Mark Kotter discusses the influence synthetic biology is having on the futu...

bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

bit.bio is partnering with the iGEM student competition, aimed at advancing the field of synthetic biology.